FOLH1 and Familial prostate cancer: Recently, new PET tracers such as radiolabeled dihydrotestosterone and radiolabeled antibody to prostate-specific membrane antigen (PSMA) have shown great potential for assessing patients' early biologic response to hormonal therapies in prostate cancer [28–30].